Boehringer Ingelheim has released details of research presented at the 29th World Veterinary Congress which shows dogs with congestive heart failure (CHF) due to myxomatous mitral valve disease (MMVD) live longer when treated with pimobendan (Vetmedin®) compared…
Boehringer Ingelheim has announced the results of an independent three-year study which demonstrates that dogs suffering from the most common type of heart failure lived longer (average time in the study of 267 days vs. 140 days) when treated with the…
Veterinary surgeons are being called on to help recruit dogs for a clinical study called EPIC - the Evaluation of Pimobendan In dogs with Cardiomegaly caused by pre-clinical mitral valve disease (MVD).
The long-term study, which is supported by Boehringer…